Inspire Pharmaceuticals announced that 430 out of the targeted 450 patients have been enrolled in its second Phase 3 clinical trial with denufosol for the treatment of CF, TIGER-2. Inspire continues to expect enrollment in TIGER-2 to be complete by the end of the year. :theflyonthewall.com
News For ISPH From The Last 14 Days
Check below for free stories on ISPH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
